<DOC>
	<DOCNO>NCT02949206</DOCNO>
	<brief_summary>The purpose study assess safety tolerability JNJ-64179375 Part 1 ( Intravenous dose ) Part 3 ( Subcutaneous dose ) potential reversibility JNJ-64179375 induce Pharmacodynamic effect coagulation parameter platelet function ( Part 2 ) healthy male participant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Immunogenicity , Pharmacodynamics JNJ-64179375 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Thrombin</mesh_term>
	<criteria>Body mass index [ weight kilogram per meter square ( kg/m^2 ) ] 18 30 kg/m^2 ( inclusive ) , body weight great 50 kilogram ( kg ) less 100 kg Generally good health basis physical examination , medical history , vital sign , laboratory test , electrocardiogram ( ECG ) perform screen and/or prior administration initial dose study drug Must sign inform consent form ( ICF ) indicate understands purpose , procedure require , study willing participate study contraceptive use men consistent local regulation regard use contraceptive method subject participate clinical study willing able adhere study visit schedule requirement , prohibition , restriction specify protocol Day 113 visit Acute illness , include upper respiratory infection ( without fever ) , within 7 day prior study drug administration major illness hospitalization within 1 month prior study drug administration Clinically significant abnormal value coagulation , hematology , clinical chemistry urinalysis screen Day 1 ( admission clinical research unit ) determine investigator appropriate designee Have smoke tobacco nicotinerelated product within 6 month prior dose agree refrain Day 113 Donated blood blood product substantial loss blood [ 500 milliliter ( mL ) ] within 3 month first administration study drug intend donate donates blood blood product study 30 day completion History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , bleed thrombotic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>